Solid Biosciences Shares Surge 8% as Market Recognises Undervalued Biotech Growth
Solid Biosciences’ stock jumps 8%, signaling renewed investor confidence in its Duchenne therapies and mid‑cap biotech upside.
- SOLID BIOSCIENCES INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read